HEXAXIM

Indications

• Whooping cough (pertussis)
• Respiratory tract infections caused by Bordetella species

Dosage

Adults: Refer to the B

Mechanism of action

Bordetella pertussis causes disease by adhering to the ciliated epithelial cells of the respiratory tract, leading to inflammation and disruption of normal respiratory function. The bacteria produce various virulence factors, including pertussis toxin, which interferes with host immune responses and causes systemic effects. The toxin primarily acts on the adenylate cyclase system, increasing cAMP levels, which disrupts cellular signaling pathways and contributes to the characteristic symptoms of whooping cough.

Pharmacodynamics

The symptoms of Bordetella infections, particularly whooping cough, are largely due to the host's immune response to the bacterial infection and the effects of the pertussis toxin. The disease progresses through stages, including the catarrhal stage (with mild symptoms), the paroxysmal stage (with severe coughing), and the convalescent stage (gradual recovery). Treatment may involve antibiotics to reduce the duration of symptoms and prevent transmission, although they do not significantly alter the course of the illness once the paroxysmal stage has begun.

Pharmacokinetics

As Bordetella is a bacterium, traditional pharmacokinetic parameters do not apply in the same way as for pharmaceuticals. The bacteria colonize the respiratory tract and can persist in the mucosal tissues, leading to prolonged symptoms. Antibiotics such as macrolides, which are commonly used to treat Bordetella infections, demonstrate variable absorption, distribution, metabolism, and excretion profiles depending on the specific drug used. For example, azithromycin has a long half-life and good tissue penetration.

Pregnancy

Bordetella pertussis vaccines are generally considered safe during pregnancy and are recommended to protect both the mother and the newborn from whooping cough.

Breast-feeding

The Bordetella pertussis vaccine can be administered during breastfeeding, as it is not known to pose a risk to nursing infants.

Storage

Store Bordetella pertussis vaccine in a refrigerator at temperatures between 2°C and 8°C. Do not freeze.

Formulations

• Bordetella pertussis vaccine (inactivated)
• Combination vaccines (e.g., DTaP - Diphtheria, Tetanus, and Pertussis)

Indications

• Diphtheria prevention through vaccination
• Management of diphtheria infection

Dosage

Children: Refer to specific treatment guidelines for pediatric doses in diphtheria cases; doses will depend on individual clinical circumstances.

Adults: Refer to specific treatment guidelines for diphtheria; doses vary based on clinical scenario and severity of infection.

Mechanism of action

Corynebacterium diphtheriae produces a potent exotoxin that inhibits protein synthesis in host cells by ADP-ribosylating elongation factor-2 (EF-2). This action disrupts the cellular protein synthesis process, leading to cell death and tissue damage, particularly in the respiratory tract.

Pharmacodynamics

The clinical manifestations of diphtheria result from the local effects of the infection and the systemic effects of the diphtheria toxin. The toxin can cause necrosis of the epithelial cells in the throat, leading to the formation of a pseudomembrane, while systemic absorption of the toxin can lead to complications such as myocarditis, polyneuropathy, and renal failure.

Pharmacokinetics

The pharmacokinetics of diphtheria toxin involves its absorption through the respiratory tract, followed by distribution to various tissues. The half-life of the toxin can vary based on the host response, and its effects can persist even after toxin levels decrease due to the irreversible binding to EF-2. The elimination of the toxin is primarily through hepatic metabolism and renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Fatigue
• Malaise
• Allergic reactions

Precautions

• Monitor for allergic reactions
• Ensure proper vaccination history is obtained

Pregnancy

The vaccine is generally considered safe during pregnancy; however, consult healthcare providers for individual assessment.

Breast-feeding

The vaccine is typically safe during breastfeeding; consult healthcare providers for individual assessment.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid vaccine

Indications

• Acute viral hepatitis
• Chronic hepatitis B
• Chronic hepatitis C
• Autoimmune hepatitis
• Alcoholic hepatitis
• Non-alcoholic fatty liver disease

Dosage

Children: Paediatric dosing also varies significantly based on the specific condition and medication. As with adult dosing, it is important to refer to the BNF for Children for specific recommendations.

Adults: Dosing for adult patients varies widely depending on the specific antiviral agent used and the type of hepatitis. It is essential to refer to specific guidelines or the BNF for precise dosing.

Mechanism of action

In viral hepatitis, the viruses typically enter liver cells and replicate, leading to cellular injury and inflammation. The immune response to the infection contributes to liver damage. Antiviral therapies aim to inhibit viral replication, either by directly targeting viral enzymes or by modulating the host immune response.

Pharmacodynamics

The pharmacodynamics of antiviral agents used in hepatitis treatment involve the inhibition of viral replication, reduction of viral load, and improvement of liver function. This can lead to a decrease in serum liver enzymes (ALT and AST) and an improvement in clinical symptoms. In chronic hepatitis B and C, sustained virologic response is the goal, indicating effective viral suppression.

Pharmacokinetics

The pharmacokinetics of antiviral medications used for hepatitis can vary significantly depending on the specific drug. Generally, these agents are absorbed from the gastrointestinal tract, metabolized in the liver, and excreted through urine or feces. The half-lives of these drugs can vary, influencing dosing schedules.

Pregnancy

Consult medical guidelines as hepatitis can pose risks during pregnancy; specific management depends on the type of hepatitis.

Breast-feeding

Consult healthcare providers, as the safety of certain hepatitis medications during breastfeeding varies.

Storage

Store in a cool, dry place away from direct sunlight; specific storage conditions may vary based on the medication used.

Indications

• Prevention of pertussis through vaccination
• Treatment of pertussis in infected individuals

Dosage

Children: For treatment of pertussis in children, refer to the BNF for Children for appropriate dosing based on age and weight.

Adults: For treatment of pertussis, refer to guidelines as specific antibiotic doses may vary based on the agent used and patient factors.

Mechanism of action

Bordetella pertussis adheres to the ciliated epithelial cells of the nasopharynx and produces several virulence factors, including pertussis toxin, which disrupts normal cellular signaling and immune responses. This leads to the characteristic symptoms of the disease, including paroxysmal coughing due to the inhibition of ciliary function and increased mucus production.

Pharmacodynamics

The pathophysiology of pertussis involves the inflammatory response triggered by the presence of the bacterium and its toxins. The pertussis toxin has multiple effects, including increasing adenylate cyclase activity, which elevates cyclic AMP levels in host cells, leading to altered immune responses. This results in the characteristic cough due to irritation of the airway and bronchoconstriction.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis is not applicable as it is a bacterium rather than a drug. However, the immune response, once triggered by either natural infection or vaccination, involves the production of antibodies that provide long-term protection against reinfection. Antibiotics, when prescribed, are absorbed systemically, metabolized in the liver, and excreted primarily through the kidneys.

Adverse effects

• Cough
• Fever
• Vomiting
• Fatigue
• Nasal congestion

Precautions

• Use with caution in patients with a history of respiratory disorders
• Monitor for secondary bacterial infections

Pregnancy

The safety of pertussis vaccination during pregnancy is generally considered acceptable; however, it is essential to consult healthcare providers for individualized recommendations.

Breast-feeding

Vaccination is considered safe during breastfeeding, but consultation with healthcare providers is advisable.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that the vaccine is not frozen.

Formulations

• Pertussis vaccine (injectable suspension)

Indications

• Poliomyelitis prevention
• Vaccination against poliovirus
• Public health immunization programs

Dosage

Children: Refer to national immunization guidelines for childhood vaccination schedules, including IPV and OPV.

Adults: Refer to national immunization guidelines, typically involving a series of vaccinations with IPV or OPV.

Mechanism of action

Poliovirus infects host cells by binding to specific receptors on the cell surface, leading to the internalization of the virus. Once inside, poliovirus releases its RNA genome, which hijacks the host's cellular machinery to replicate and produce viral proteins. This replication can cause cell lysis and inflammation, leading to symptoms of the disease.

Pharmacodynamics

Poliovirus primarily targets motor neurons in the spinal cord and brainstem, resulting in cell death and, subsequently, muscle weakness or paralysis. The severity of the disease varies significantly, with many infections being asymptomatic, while a minority progress to paralytic disease. The immune response to the infection plays a crucial role in determining the outcome.

Pharmacokinetics

The pharmacokinetics of poliovirus is characterized by its ability to survive in the gastrointestinal tract, where it replicates before entering the bloodstream. The virus does not undergo conventional pharmacokinetic processes such as absorption, distribution, metabolism, or excretion like typical drugs, as it is a living organism. The duration of viral shedding can vary, typically lasting from a few weeks to several months, depending on the individual’s immune response.

Adverse effects

• Mild fever
• Fatigue
• Headache
• Sore throat
• Nausea
• Vomiting
• Diarrhea
• Flu-like symptoms
• Rarely, paralytic poliomyelitis

Precautions

• Monitor for signs of allergic reactions
• Patients with immunocompromised states should be assessed carefully
• Individuals should be screened for history of vaccine-associated paralytic poliomyelitis

Pregnancy

The inactivated poliovirus vaccine (IPV) is considered safe during pregnancy. Live attenuated vaccines are generally avoided.

Breast-feeding

IPV is safe for breastfeeding mothers. Live attenuated vaccines may have specific recommendations.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid